An interventional study of Health Linkage and Overdose Education in Substance Use, HIV Infections and HCV Infection, sponsored by April M Young. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-21.
Sponsored by April M Young · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 72 studies in Drug Overdose with a site in United States — 17 open to participants now, 28 under way, none of them phase 3. Drug Overdose · United States.
Among the 72 studies in Drug Overdose with a site in United States, this one is the 28th largest by enrollment of the 58 interventional ones that give a count, is one of 10 that started in 2019, is one of 51 with no phase, and was the 32nd registered.
104 studies on the registry are indexed under Drug Overdose; 22 are open to participants now.
Browse Drug Overdose studies →17 of the 72 studies in Drug Overdose with a site in United States are open now. Recruiting first, the newest first:
Boston Medical Center · Sites in United States
Ages 13+
San Francisco Department of Public Health · Sites in United States
Ages 18+ · Healthy volunteers
University of Wisconsin, Madison · Sites in United States
Ages 18+
Michele Staton · Sites in United States
Ages 18+ · Women only · Healthy volunteers
NYU Langone Health · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 13 Drug Overdose studies recruiting now, 12 (92%) set no upper age limit and 1 (8%) stops at 75 or younger; 3 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
72 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 10 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 234 is above the median of 124 across 76 interventional studies indexed under Drug Overdose.
Median enrollment 182 across the 58 interventional studies, 217 across the 14 observational. Of the 40 that completed or were terminated, 18 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 72 have an industry lead sponsor. The 10 most frequent:
April M Young is the lead sponsor of 2 studies on the registry; none are open to participants now.
April M Young has 2 studies filed under Drug Overdose — fewer than ten, so there is no comparison to draw.
8 of the studies in Drug Overdose with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07022717Boston Medical CenterA Universal Primary Care Based Intervention to Reduce Youth Overdose Risk | 2026-11 |
| NCT05320835Johns Hopkins Bloomberg School of Public HealthA Setting Focus Overdose Prevention Intervention | 2026-12-01 |
| NCT06236087NYU Langone HealthOverdose Prevention Centers and Behavioral Health | 2026-12-31 |
| NCT07170072NYU Langone HealthShelter HArm Reduction Evaluation | 2027-03-31 |
| NCT05657106April M YoungKentucky Outreach Service Kiosk (KyOSK): Reducing HIV, HCV, and Overdose Risk | 2027-05-31 |
Add all 8 to your calendar (.ics) → With an account.
Among the 72 studies in Drug Overdose with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will test the effects of an intervention to reduce substance use and related harms among people leaving rural jails or otherwise involved in the criminal justice system. This study will compare people in a health linkage intervention with people who will get overdose (OD) education. Everyone will take part in the baseline and follow-up surveys and receive OD education. Participants will be assigned to one of the two groups by chance based on when they are enrolled to the study and if their county is randomly assigned to an intervention or a comparison condition. By doing this study, the investigators hope to learn if providing linkage to health services along with HIV, hepatitis C virus (HCV), and overdose education to people leaving rural jails or otherwise involved in the criminal justice system will reduce substance use and related harms.
The overarching objective of this study is to determine the effectiveness of an evidence-based community response project using a community randomized trial. Specifically, the investigators will test the effect of an intervention to reduce substance use and related harms among people re- entering the community from rural jails or otherwise recently involved in the criminal justice system (out on bond, under warrant for arrest, arrested, on pre-trial supervision, probation or parole, court-involved, or under home incarceration with digital monitoring). This study will compare people in a health navigation intervention with a comparison group of people who will get overdose education. Everyone will take part in follow-up surveys for up to 6 months after release. The intervention is a health navigation intervention designed to reduce substance use disorder (SUD) and increase engagement in the SUD care cascade; reduce vulnerability to HIV, sexually transmitted infections (STIs), and HCV and increase engagement in the HIV, STI, and HCV care cascades; and reduce vulnerability to overdose deaths among adults who use drugs and are leaving local jails or otherwise involved in the criminal justice system. The intervention is based on enhancements to START, a Center for Disease Control-recognized, evidence-based, individual-level intervention designed to reduce HIV/STI/HCV risk.
START core components: (1) Hold pre- and post-release program sessions with clients transitioning back to the community from a correctional setting; (2) Use a client-focused incremental risk reduction approach; (3) Use assessment \& documentation tools to provide structure; (4) Hire program staff that are familiar with HIV/STIs/HCV prevention and with the specific needs of people being released; (5) Staff /client relationships must be maintained post-release; (6) Conduct enrollment and schedule two pre-release program sessions within 60 days of a client's release that: a. give HIV/STI/HCV information; b. review client's HIV/STI/HCV risk; c. identify transitional needs; d. develop a personalized risk reduction and transitional plan; e. make facilitated referrals; 7) Schedule four post-release sessions to review and update the risk reduction/ transitional plan(s) and provide facilitated referrals; (8) Provide condoms at each post-release session; (9) Actively maintain contact with clients.
The investigators will modify START a priori as follows: 1) Though originally designed for young men, START has been successfully applied to women leaving correctional settings. The investigators will implement START with all genders; 2) START originally targeted incarcerated people preparing to leave correction facilities. The investigators will continue to target individuals who are incarcerated but also expand the target population to people who are involved in other parts of the criminal justice system (e.g., those out on bond, under warrant for arrest, arrested, court-involved; those on probation, parole or pre-trial supervision; and individuals under home incarceration with digital monitoring [an ankle monitoring program]). Individuals who are not incarcerated will be recruited in the communities. 3) All intervention sessions will be conducted in the community setting (post-release for those recruited in jails). 4) START's post-release sessions primarily occurred in homes and community venues, such as restaurants. Staff who will deliver START will be stationed primarily within the local department of health (DOH); 5) To enhance START's impact on drug use and HIV/HCV-related harms (e.g., drug injection frequency), the investigators will integrate the NIDA (National Institute on Drug Abuse) Standard HIV intervention into START, including rapid HIV and HCV antibody testing and counseling. In addition, START interventionists will distribute harm reduction supplies at the first intervention session with people who inject drugs (PWID). The NIDA Standard has been demonstrated to reduce drug use frequency, high-risk injection practices, and sexual risk; 6) START was not designed to reduce overdoses. The investigators will integrate an interactive training with animated scenarios and narration on preventing, recognizing, and responding effectively to an opioid OD. Participants in the intervention group will receive naloxone (not all participants will get naloxone), at their first intervention session. Interventionists will encompass OD in risk reduction motivational interviewing. 7) To accommodate participants who are not able to visit the study office in-person, data collection and intervention sessions will be conducted remotely via phone or videoconferencing.
CARE2HOPE covers the following counties: Rowan, Bath, Morgan, Menifee, Elliott, Lee, Owsley, Wolfe, Perry, Letcher, Leslie, Knott. Research staff will recruit participants from a) jails, b) Probation, Parole and Pre-Trial Services c) digital jails (i.e. home incarceration with digital monitoring programs); d) peer referral; e) existing participants in CARE2HOPE and other University of Kentucky studies, including PROUD-R2 (Peer-Based Retention of People Who Use Drugs in Rural Research) and SNAP (Social Networks among Appalachian People), who have consented to be contacted to learn about future studies; f) harm reduction and social service programs serving people who use drugs; and g) community-based organizations serving the 12 CARE2HOPE counties. Recruitment in jails will involve jails either located in CARE2HOPE counties or counties that have contracts with them to incarcerate their residents. The intervention sessions and data collection will be delivered by research staff called "Rural Health Navigators" or "REHNs". Participants are assigned to one of the two groups by chance based on when they are enrolled to the study and when their county is randomly chosen to start the project. Counties were originally randomized using a stepped wedge design. The counties were then randomized in November 2020, accounting for a new study design. The investigators randomized 12 study counties to two groups. In Months 1-6 six counties randomly assigned to Group 1 will recruit participants to the intervention, while in the remaining six counties (Group 2) the participants will be enrolled into a control condition. The investigators anticipate an average enrollment of 40 participants per county per arm, with a total final sample size for the trial of 960 (n=480intervention, n=480comparison). After a county has met its target enrollment in both conditions, the intervention and comparison activities will no longer be offered in that county.
Originally, the CARE2HOPE trial gathered data in three waves: at baseline, before the intervention had been delivered in the intervention counties; at three months post baseline, just after the intervention had been completed; and at six months post baseline, to support analyses of intervention decay. On June 24th 2022, the CARE2HOPE Data Safety Monitoring Board (DSMB) met to determine whether the trial could limit data collection to two waves - baseline and the 3-month follow up - and still ethically meet its aims. The DSMB voted to drop the six-month wave of data collection recognizing that:
104 studies on the registry are indexed under Drug Overdose; 22 are open to participants now.
This study's enrollment of 234 is above the median of 124 across 76 interventional studies indexed under Drug Overdose.
Browse Drug Overdose studies →April M Young is the lead sponsor of 2 studies on the registry; none are open to participants now.
Compared within Drug Overdose, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Substance-Related Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
OR
OR
Exclusion criteria:
Research staff will: 1) meet with participants in person or virtually to ask questions about drug use and related behaviors, service access, and personal goals; provide overdose education and help develop a plan for reducing risks and accessing services; conduct drug testing, offer HIV and HCV testing and counseling, naloxone, and harm reduction supplies, and connection with needed services; 2) follow up with participants monthly for three months to help overcome challenges; and 3) six months post-enrollment, contact participants to conduct drug testing. Participants will complete surveys at baseline, 3 months, and 6 months
Behavioral: Health Linkage · Behavioral: Overdose Education
The investigators will initiate the comparison group in Group 2 counties six months before the intervention begins. Research staff will conduct an overdose intervention with the comparison cohort. This will occur pre-release if individual is recruited in jail. The comparison group participants will watch a video on preventing, recognizing, and responding effectively to an opioid OD, accompanied by information about Kentucky's Good Samaritan Law and Naloxone Access Law. Research staff will answer questions after the video. Individuals will receive a Community Resource Guide at this visit. As in the intervention group, the comparison group participants will complete surveys at the baseline (in jail if recruited in jail, in a community setting if recruited in the community), and at 3 months and 6 months after the baseline. Surveys will be identical to those delivered to the intervention cohort.
Behavioral: Overdose Education
Research staff will: 1) help participants set goals and reduce their health risks by helping them to reflect on personal drug use, sexual relationships, and their consequences in the context of personal values and goals; 2) help link participants to services that they need and want; 3) offer participants the option of HIV and hepatitis C testing, provide the test result, and provide post-test counseling; and 4) provided participants nasal spray naloxone (Narcan) to carry with them in case they encounter someone who has an opioid overdose or in case they have an opioid overdose and a friend can use the naloxone to respond.
Participants will complete a 10-minute overdose education training video on preventing, recognizing, and responding effectively to an opioid OD.
Change in Substance Use Frequency
Item:Self-reported frequency of substance use to get high in past 30 days (continuous variable) Source: Rural opioid initiative (ROI Harmonized UG3 Survey) Harmonized UG3 Survey
Time frame: assessed at 3 months and 6 months after the baseline, change at 3 months reported
Change in Engagement in HIV Risk Behaviors - Receptive Syringe Sharing
Item: Self-reported recent (past 30 days) frequency of engaging in the HIV risk behavior of using a syringe that had been previously used by someone else (continuous; number and proportion) Source: ROI Harmonized UG3 Survey
Time frame: assessed at 3 months and 6 months after the baseline, change at 3 months reported
Change in Engagement in HIV Risk Behaviors - Condomless Sex
Item: Self-reported recent (past 30 days) frequency of condomless anal or vaginal sex (continuous; number and proportion) Source: ROI Harmonized UG3 Survey
Time frame: assessed at 3 months and 6 months after the baseline, change at 3 months reported
Change in Engagement in HCV Risk Behaviors - Receptive Syringe Sharing
Item: Self-reported recent (past 30 days) frequency of engaging in the hepatitis C risk behavior of using a syringe that had been previously used by someone else (continuous; number and proportion) Source: ROI Harmonized UG3 Survey
Time frame: assessed at 3 months and 6 months after the baseline, change at 3 months reported
Change in Engagement in HCV Risk Behaviors - Shared Injection Equipment
Item: Self-reported recent (past 30 days) frequency of shared cookers, cotton, spoon, or water (continuous; number and proportion) Source: ROI Harmonized UG3 Survey
Time frame: assessed at 3 months and 6 months after the baseline, change at 3 months reported
Change in Frequency of Opioid Overdose
Item:Self-reported recent (past 90 days) number of times overdosed (ordinal, continuous) Source: Modified from ROI Harmonized UG3 Survey
Time frame: assessed at 3 months and 6 months after the baseline, change at 3 months reported
Change in Frequency of Receptive Syringe Sharing
Item:Self-reported recent (past 30 days) frequency of using a syringe that had been previously used by someone else (continuous; number and proportion) Source: ROI Harmonized UG3 Survey
Time frame: assessed at 3 months and 6 months after the baseline, change at 3 months reported
Change in Frequency of Injection Drug Use
Item: Self-reported recent (past 30 days) frequency of injection (ordinal, continuous) Source: ROI Harmonized UG3 Survey
Time frame: assessed at 3 months and 6 months after the baseline, change at 3 months reported
Change in Number of Days Carrying Naloxone
Item:Self-reported recent (past 90 days) number of days carrying naloxone (continuous) Source: Modified from ROI Harmonized UG3 Survey
Time frame: assessed at 3 months and 6 months after the baseline, change at 3 months reported
Change in Evidence-based Responses to a Witnessed Overdose
Item: Self-reported recent (past 90 days) engagement in evidence-based responses (i.e., called 911, gave naloxone, stayed until an ambulance or police arrived, transported person to the hospital) to a witnessed overdose by self or other bystanders (nominal) Source: CDC NHBS Supplemental overdose items
Time frame: assessed at 3 months and 6 months after the baseline, change at 3 months reported
Change in Number of Days on Medication for Opioid Use Disorder (MOUD) Among Participants for Whom MOUD is Indicated
Item:Self-reported recent (past 90 days) frequency of being on MOUD (continuous) Source: Modified from ROI Harmonized UG3 Survey
Time frame: assessed at 3 months and 6 months after the baseline, change at 3 months reported
Change in Linkage to Follow-up HCV Testing Among Those Who Test HCV Antibody Positive
Item:Self-reported recent (past 90 days) access to follow-up HCV RNA testing (nominal); (among participants that had been told ever infected with HCV at baseline - our HCV testing item is not specific to RNA testing, ALL reporting HCV diagnosis at baseline were tested at baseline) Source: ROI Harmonized UG3 Survey
Time frame: assessed at 3 months and 6 months after the baseline, change at 3 months reported
Change in Linkage to Treatment Among Those Who Test HCV RNA Positive
Item: Self-reported recent (past 90 days) frequency of receiving treatment among those who test RNA positive (binary) Source: Modified from ROI Harmonized UG3 Survey
Time frame: assessed at 3 months and 6 months after the baseline, change at 3 months reported
Change in Proportion of Syringes Obtained From Syringe Service Program Among Participants Who Inject Drugs
Item: Self-reported proportion of recent (past 90 days) injections that involved a new, sterile syringe obtained from a syringe service program (continuous, proportion) Source: ROI Harmonized UG3 Survey
Time frame: assessed at 3 months and 6 months after the baseline, change at 3 months reported
| Milestone | Health Linkage | Overdose Education |
|---|---|---|
| Started | 111 | 123 |
| Completed | 67 | 81 |
| Not completed | 44 | 42 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Removed for harassing staff | 0 | 1 |
| Withdrew: Lost to follow-up | 44 | 40 |
Item:Self-reported frequency of substance use to get high in past 30 days (continuous variable) Source: Rural opioid initiative (ROI Harmonized UG3 Survey) Harmonized UG3 Survey
| Days of drug use | Health Linkage | Overdose Education |
|---|---|---|
| Change in Substance Use Frequency | -11.2 (-14.8 to -7.7) | -5.5 (-8.4 to -2.6) |
Item: Self-reported recent (past 30 days) frequency of engaging in the HIV risk behavior of using a syringe that had been previously used by someone else (continuous; number and proportion) Source: ROI Harmonized UG3 Survey
| Receptive syringe shares | Health Linkage | Overdose Education |
|---|---|---|
| Change in Engagement in HIV Risk Behaviors - Receptive Syringe Sharing | -4.0 (-9.0 to 1.0) | 5.1 (-7.0 to 17.3) |
Item: Self-reported recent (past 30 days) frequency of condomless anal or vaginal sex (continuous; number and proportion) Source: ROI Harmonized UG3 Survey
| Number of times had condomless sex | Health Linkage | Overdose Education |
|---|---|---|
| all participants | -0.7 (-3.9 to 2.5) | -1.7 (-4.6 to 1.3) |
| participants with > 1 sex partner | -0.4 (-4.0 to 3.2) | -2.0 (-5.9 to 1.8) |
Item: Self-reported recent (past 30 days) frequency of engaging in the hepatitis C risk behavior of using a syringe that had been previously used by someone else (continuous; number and proportion) Source: ROI Harmonized UG3 Survey
| Receptive syringe shares | Health Linkage | Overdose Education |
|---|---|---|
| Change in Engagement in HCV Risk Behaviors - Receptive Syringe Sharing | -4.0 (-9.0 to 1.0) | 5.1 (-7.0 to 17.3) |
Item: Self-reported recent (past 30 days) frequency of shared cookers, cotton, spoon, or water (continuous; number and proportion) Source: ROI Harmonized UG3 Survey
| Number of times shared equipment | Health Linkage | Overdose Education |
|---|---|---|
| Change in Engagement in HCV Risk Behaviors - Shared Injection Equipment | -10.6 (-18.2 to -3.0) | 4.5 (-7.7 to 16.8) |
Item:Self-reported recent (past 90 days) number of times overdosed (ordinal, continuous) Source: Modified from ROI Harmonized UG3 Survey
| Number of times overdosed | Health Linkage | Overdose Education |
|---|---|---|
| Change in Frequency of Opioid Overdose | -0.25 (-0.6 to 0.10) | -0.59 (-1.2 to 0.02) |
Item:Self-reported recent (past 30 days) frequency of using a syringe that had been previously used by someone else (continuous; number and proportion) Source: ROI Harmonized UG3 Survey
| Receptive syringe shares | Health Linkage | Overdose Education |
|---|---|---|
| Change in Frequency of Receptive Syringe Sharing | -4.0 (-9.0 to 1.0) | 5.1 (-7.0 to 17.3) |
Item: Self-reported recent (past 30 days) frequency of injection (ordinal, continuous) Source: ROI Harmonized UG3 Survey
| Number of times injected drugs | Health Linkage | Overdose Education |
|---|---|---|
| Change in Frequency of Injection Drug Use | -33.7 (-49.2 to -18.3) | -19.5 (-30.2 to -8.7) |
Item:Self-reported recent (past 90 days) number of days carrying naloxone (continuous) Source: Modified from ROI Harmonized UG3 Survey
| Number of days carrying naloxone | Health Linkage | Overdose Education |
|---|---|---|
| Change in Number of Days Carrying Naloxone | 4.5 (-8.5 to 17.5) | 0 (-9.7 to 9.7) |
Item: Self-reported recent (past 90 days) engagement in evidence-based responses (i.e., called 911, gave naloxone, stayed until an ambulance or police arrived, transported person to the hospital) to a witnessed overdose by self or other bystanders (nominal) Source: CDC NHBS Supplemental overdose items
| Evidence-based responses to overdose | Health Linkage | Overdose Education |
|---|---|---|
| Change in Evidence-based Responses to a Witnessed Overdose | 0.1 (-0.9 to 1.1) | -0.2 (-0.6 to 0.1) |
Item:Self-reported recent (past 90 days) frequency of being on MOUD (continuous) Source: Modified from ROI Harmonized UG3 Survey
| Days on MOUD | Health Linkage | Overdose Education |
|---|---|---|
| Change in Number of Days on Medication for Opioid Use Disorder (MOUD) Among Participants for Whom MOUD is Indicated | 23.5 (-0.4 to 47.3) | 8.2 (-7.1 to 23.6) |
Item:Self-reported recent (past 90 days) access to follow-up HCV RNA testing (nominal); (among participants that had been told ever infected with HCV at baseline - our HCV testing item is not specific to RNA testing, ALL reporting HCV diagnosis at baseline were tested at baseline) Source: ROI Harmonized UG3 Survey
| Percent with follow-up HCV test | Health Linkage | Overdose Education |
|---|---|---|
| Change in Linkage to Follow-up HCV Testing Among Those Who Test HCV Antibody Positive | -40 | -33.3 |
Item: Self-reported recent (past 90 days) frequency of receiving treatment among those who test RNA positive (binary) Source: Modified from ROI Harmonized UG3 Survey
| Percent linked to treatment | Health Linkage | Overdose Education |
|---|---|---|
| Change in Linkage to Treatment Among Those Who Test HCV RNA Positive | 0 | -5.9 |
Item: Self-reported proportion of recent (past 90 days) injections that involved a new, sterile syringe obtained from a syringe service program (continuous, proportion) Source: ROI Harmonized UG3 Survey
| Percentage of syringes obtained at SSP | Health Linkage | Overdose Education |
|---|---|---|
| Change in Proportion of Syringes Obtained From Syringe Service Program Among Participants Who Inject Drugs | 12.4 (-10.9 to 35.7) | 0 (-11.2 to 11.2) |
Collected over 3 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Health Linkage | 0/111 (0%) | 10/111 (9%) | 5/111 (4.5%) |
| Overdose Education | 1/123 (0.8%) | 12/123 (9.8%) | 27/123 (22%) |
| Event | Health Linkage | Overdose Education |
|---|---|---|
| Non Fatal OverdoseGeneral disorders | 7/111 | 7/123 |
| Emergency Room visit or HospitalizationGeneral disorders | 3/111 | 4/123 |
| DeathGeneral disorders | 0/111 | 1/123 |
| Event | Health Linkage | Overdose Education |
|---|---|---|
| Infected with hepatitis CInfections and infestations | 5/111 | 24/123 |
| Believed correctional officers could hear interviewGeneral disorders | 0/111 | 1/123 |
| problems with family members, friends, or partners and infected with hepatitis CSocial circumstances | 0/111 | 1/123 |
| Believed correctional officers could hear interview and infected with hepatitis CGeneral disorders | 0/111 | 1/123 |
One participant from the Health Linkage Arm did not have demographic data available
| Age, Continuous(years) | Health Linkage | Overdose Education | Total |
|---|---|---|---|
| Mean | 37.2 ± 8.4 | 38.4 ± 7.1 | 37.8 ± 7.7 |
| Sex: Female, Male(Participants) | Health Linkage | Overdose Education | Total |
|---|---|---|---|
| Female | 58 | 63 | 121 |
| Male | 52 | 60 | 112 |
| Ethnicity (NIH/OMB)(Participants) | Health Linkage | Overdose Education | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 0 | 2 |
| Not Hispanic or Latino | 107 | 122 | 229 |
| Unknown or Not Reported | 1 | 1 | 2 |
| Race (NIH/OMB)(Participants) | Health Linkage | Overdose Education | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 1 |
| White | 106 | 120 | 226 |
| More than one race | 0 | 2 | 2 |
| Unknown or Not Reported | 2 | 1 | 3 |
| Region of Enrollment(participants) | Health Linkage | Overdose Education | Total |
|---|---|---|---|
| United States | 110 | 123 | 233 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Data from the University of Kentucky are required to be submitted to the University of Washington as part of the NIH-funded Rural Opioid Initiative (ROI) data harmonization project. The University of Washington Data Harmonization Coordinating Center (DCC) will be harmonizing data across 8 ROI studies in order to create new, harmonized datasets to be used for analyses across the consortium. The University of Washington and other ROI grantees will perform data analyses on these data for peer-reviewed publication. The harmonized datasets will be provided to other ROI grantees as required for analysis and will be considered under the umbrella of mandated DCC activities. No third parties outside of the ROI will be given access to this harmonized data. Harmonized datasets will be built to specific project concept proposals, and all project proposals must be reviewed and approved by the ROI consortium's Publications Working Group before distribution of the customized dataset.
Ran from Nov 2019 to primary completion in Oct 2022, 35 months.
Results were first posted in Dec 2023, 1 year 1 month after primary completion.
Of 47 non-industry interventional studies with no phase under Drug Overdose, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 49. This study's 35 months is above that.
Counting every sponsor, half of 47 studies reached it within 31 months; a quarter within 13 and three quarters within 49.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
April M Young